It is proposed to set aside a goodwill impairment provision of nearly 0.9 billion yuan. China National Accord Medicines Corporation's revenue and net profit are expected to decline in 2024 | Quick Announcement.

① Due to the combined impact of intensified market competition and other factors, China National Accord Medicines Corporation expects a decline in both revenue and Net income for 2024. ② The company plans to make an impairment provision totaling 1.094 billion yuan for credit impairment losses and asset impairment losses.

cls.cnMar 17 10:13 ET

0.124 billion USD! FOSUN PHARMA and United Family Healthcare "completely part ways" | Quick announcement.

① FOSUN PHARMA's subsidiary plans to sell a 6.6% stake in the symbol company for 0.124 billion USD; ② The relationship between FOSUN PHARMA and Huameijia can be traced back to 2009; ③ After this Trade is completed, FOSUN PHARMA will completely exit Huameijia.

cls.cnMar 13 11:26 ET

It's adding insult to injury! JiangSu WuZhong Pharmaceutical Development is beset by three major Bearish factors. Will the agency rights for Tongyan needles change? | Quick Announcement

① JiangSu WuZhong Pharmaceutical Development is currently facing uncertainties such as allegations of violating information disclosure laws, subsidiary's alleged assistance in tax fraud, and changes in agency rights for AestheFill within China. ② Compared to the beginning of the year, the company's stock price has fallen over 35%, reaching a new low for this year.

cls.cnMar 12 10:49 ET

The late-night announcement of the "Demon King" triggered a "Moment of Crisis" as Hainan Shuangcheng Pharmaceuticals' restructuring failure sounded the alarm for (Delisted).

1. Hainan Shuangcheng Pharmaceuticals suddenly announced at midnight that it would terminate the acquisition of Aola shares. After planning this Trade last year, the stock price once surged 7 times with "21 boards in 23 days"; 2. The cost differences of the equity obtained by the 25 counterparties faced by the company are significant, and the cost pressure for institutions that entered during Pre-IPO financing may be higher; 3. The company's operating situation is poor and is facing Special Treat, and the failed restructuring may push it into a more dangerous situation.

cls.cnMar 10 20:51 ET

JiangSu WuZhong Pharmaceutical Development is in trouble! A subsidiary has been sued for assisting in a tax fraud case and is also under investigation for violation of information disclosure regulations.

① JiangSu WuZhong Pharmaceutical Development announced that its subsidiary and the Chairman are being prosecuted for assisting in tax fraud of 0.242 billion yuan, and are also being investigated by the Securities Regulatory Commission for information disclosure violations, which may pose a risk of (Delisted); ② although the two incidents are closely timed, legal experts say that no correlation can be discerned at present; ③ since the third quarter of last year, JiangSu WuZhong's performance has shown significant improvement; ④ some investors have declared "they will protect their legitimate rights and interests" due to the significant fluctuations in stock prices.

cls.cnMar 7 10:07 ET

Guizhou Xinbang Pharmaceutical's subsidiary is embroiled in a bribery scandal; what is the impact?

① Company personnel stated that this matter currently has no impact on the company's operation, and the subsidiary mainly engages in in-hospital pharmaceutical wholesale. Even if penalized later, it will not involve qualification issues. ② Industry experts believe that the short-term impact is significant, while the long-term impact is minimal. In the short term, the principal company may be listed as untrustworthy due to the crime of unit bribery, which would exclude it from the bidding procurement of local hospitals in Guizhou for a period. However, in the long term, since it is not a quality issue, there are opportunities for repair.

cls.cnMar 4 09:08 ET